Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.